16 September 2026 editorial review · Item
ViCapsys / MGH CXCL12-alginate islet encapsulation (VICAPSYN): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: Primate papers show small pilot studies, reduced islet viability and C-peptide detectable through 13 weeks, not insulin independence. Corrected contradictory claims that no animal achieved insulin independence and every study was drug-free: mouse glycemic correction occurred, and the NOD combination used costimulation blockade.
- Primary publication/regulatory sources checked or consulted: xen.70098; xen.12826; TXD.0000000000000890; ajt.15308; ajt.13049; xen.12577; j.pharmthera.2018.08.011.